(AOF) – Pharnext (+111% to 0.24 euros) jumps after announcing today that it has received two binding offers with a view to signing an agreement to promote PXT3003, its most advanced drug candidate currently under study pivotal Phase III clinical trial (Premier trial) in Charcot-Marie-Tooth disease type 1A (CMT1A), a rare debilitating peripheral neuropathy. “In both cases, the estimated global floor valuation, including revenues indexed to sales of the future drug, amounts to more than 250 million euros,” indicates Pharnext.
One of the offers concerns a licensing agreement with limited geographic exclusivity in the United States and Europe, allowing Pharnext to subsequently initiate new negotiations in other territories. The other offer concerns a purchase of the entire intellectual property of PXT3003 and the attached contracts with a view to global exploitation, outside Chinese territory. Stakeholder names and financial details remain confidential at this time.
Depending on the different projections of future revenues linked to sales of the drug, total revenues could reach between 250 million euros and up to 800 million euros for Pharnext over the entire life of the rights.
The signing of such agreements could make it possible to cover Pharnext’s financing needs and thus put an end to the financing line by issuing OCEANE-BSA subscribed by Global Tech Opportunities 13.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.